Pharmacokinetics of Diclazuril in the Plasma and Cerebrospinal Fluid of Healthy Adult Horses After a Single Oral Dose Administered as a Pelleted Topdressing Authors: Elizabeth J Treece, Kate L Hepworth‐Warren, Mark G Papich, Philip D van Harreveld, Anthony T Blikslager, Faith E Church, Kaitlyn B Harbor, Sara J Erwin‐Craig Published: 2026 ABSTRACT ABSTRACTEquine protozoal myeloencephalitis can cause acute infections with rapid onset of neurologic signs, necessitating immediate empiric therapy with antiprotozoal medication. The objective of the study was to identify when concentrations of diclazuril reached the MIC of Sarcocystis neurona in CSF (1 ng/mL) of healthy adult horses after a single oral dose. Six healthy adult horses were used. Blood and CSF were collected from indwelling intravenous jugular catheters and intrathecal catheters in the lumbosacral space prior to drug administration and then at 1‐, 4‐, 8‐, 12‐, 16‐, 24‐, 48‐, 72‐, 96‐, 120‐, 144‐, 168‐, and 192‐h post‐administration of a 1 mg/kg dose of pelleted diclazuril administered by mouth in 8 oz of sweet feed. Samples were centrifuged then plasma and CSF supernatant were separated and frozen at −80°C until analysis. Diclazuril concentrations were analyzed with a liquid chromatography‐mass spectrometer assay developed specifically for this study. Plasma concentrations of diclazuril peaked at 48 h with a mean concentration of 395.6 ± 109.4 ng/mL. CSF concentrations of diclazuril peaked at 24 h (mean concentration 9.0 ± 5.4 ng/mL) but achieved the MIC of S. neurona 12 h after administration (mean concentration 2.6 ± 1.8 ng/mL) and remained above MIC for the duration of the sampling period. In conclusion, pelleted diclazuril at 1 mg/kg reaches concentrations in the CSF above the MIC for S. neurona in healthy horses 12 h after a single oral dose.Keywords: antiprotozoal, equine protozoal myeloencephalitis, intrathecal catheter, Sarcocystis neurona Introduction Diclazuril (Protazil, Merck Animal Health, Summit, NJ, USA), which is approved for the treatment of equine protozoal myeloencephalitis (EPM), is marketed as a 1.56% alfalfa‐based pellet that is administered once daily by mouth at a dose of 1 mg/kg for 1 month. No loading dose or coadministration with other substrates (corn oil) is described for diclazuril (Schering‐Plough Animal Health Corp 2007; Furr and Kennedy 2020). To reduce long‐term deleterious effects of protozoal migration and inflammation, some clinical cases that display acute and severe clinical signs may be treated before, and while awaiting results of, diagnostic testing, as there are no reported adverse side effects of diclazuril, even when administered at 50 times the labeled dose for 42 days (Schering‐Plough Animal Health Corp 2007). Therefore, achievement of adequate plasma concentrations and rapid penetration to the central nervous system is paramount. The published in vitro IC95 (concentration of drug which inhibits biological activity by 95%) of diclazuril for Sarcocystis neurona is 1 ng/mL (Lindsay and Dubey 2000). The steady‐state concentration of diclazuril in plasma is 2000–2500 ng/mL, with cerebrospinal fluid (CSF) concentrations typically expected to be 1%–5% of plasma concentrations (Schering‐Plough Animal Health Corp 2007; Dirikolu et al. 1999). Despite EPM being recognized as a disease in 1974 and FDA‐approved treatments being available for close to 25 years, to the authors' knowledge, only one study has directly measured CSF concentrations of currently available therapeutics before 7 days of treatment, and CSF concentrations of diclazuril have not previously been measured after a single dose (Furr and Kennedy 2020; Reed et al. 2012). It is not feasible to collect tissues from the CNS (brain or meninges) in healthy experimental horses; therefore, we used CSF collection as a surrogate for measuring penetration across the blood‐CSF barrier (Shen et al. 2004). This may provide evidence of similar penetration across the blood–brain barrier, with an understanding that CSF concentrations may not be equal to CNS concentrations needed for successful treatment (De Lange and Danhof 2002). The objective of this study was to measure diclazuril concentrations in plasma and CSF after a single oral dose of diclazuril administered as a pelleted top dressing. We hypothesized that CSF concentrations of diclazuril would reach the MIC for S. neurona within 24 h of a single oral dose of diclazuril administered as a pelleted topdressing. Materials and Methods Animals Six healthy university‐owned adult horses were enrolled in the study. There were 4 mares and 2 geldings aged 7–19 years (median 11.5 years), weighing 514 to 610 kg (median 549 kg). Breeds included 2 Warmbloods, 3 Quarter Horses, and 1 Thoroughbred. Horses were considered healthy based on physical exam parameters. All horses were neurologically normal based on a neurologic examination performed the day prior to study commencement by a large animal internal medicine specialist (K.L.H.‐W.) and a resident in an equine internal medicine residency training program (E.J.T.). Physical examinations were performed daily and remained within normal limits for all horses throughout the sampling period. SnSAG2, 4/3 ELISA serum:CSF titer ratios for S. neurona and NhSAG1 ELISA serum:CSF titer ratios for N. hughesi were submitted (EDS, Kentucky) at the beginning of the study period and tested negative for all animals. All procedures were approved by the North Carolina State University Institutional Animal Care and Use Committee. IV Catheter Placement Following a 24‐h acclimation period, intravenous jugular catheters (IVC, 14 g, Millpledge, Thousand Oaks, CA) were aseptically placed to facilitate frequent blood sampling. Intravenous catheters were flushed every 8 h with 12 mL of a heparin‐saline solution and bandaged as necessary to discourage inadvertent removal and monitored for any signs of thrombophlebitis. Intrathecal Catheter Placement Following a minimum of 24 h acclimation period, all horses were restrained in standing stocks and sedated with intravenous detomidine (Dormosedan, 0.01–0.02 mg/kg IV, Zoetis, Parsippany, NJ) and butorphanol (Torbugesic, 0.01–0.2 mg/kg IV, Zoetis, Parsippany, NJ) for intrathecal catheter (ITC) placement in the lumbosacral (LS) space. Additional doses of detomidine and butorphanol were administered, and a nose twitch was applied as needed for restraint throughout the procedure. An approximately 30 cm (Furr and Kennedy 2020) area centered over each horse's LS space based on anatomical landmarks (dorsal midline, approximately 0.5–1 cm cranial to the most superficial aspect of the tuber sacrale) was clipped and aseptically prepared with at least 7 min of antiseptic contact time (Aleman et al. 2007). Lidocaine hydrochloride (Lidocaine Hydrochloride Injectable‐2%, Phoenix, St. Joseph MO, 0.12 mg/kg) was injected into the subcutaneous tissues and muscle at the intended needle insertion site before a final aseptic preparation and alcohol rinse. An epidural catheter kit (20 g epidural catheter kit, MILA Int, Hebron, KY) was utilized as previously described (Goehring et al. 2006). A 6‐in. 18 G Tuohy needle was passed through the lumbosacral space into the subarachnoid space, confirmed with CSF aspiration. The 20 g 90 cm catheter was passed through the Tuohy needle slowly until approximately the level of the L1‐L3 vertebrae. The clamp‐style adapter was applied to the end of the catheter and patency was confirmed with CSF aspiration prior to Tuohy needle removal. The adapter was then removed to allow for removal of the Tuohy needle and the catheter was trimmed to a desirable length to facilitate bandaging and accessibility. The adapter was reapplied to the end of the catheter and an injection cap was attached. At the level of the insertion, a white suture wing was placed with a combination of tissue glue (Vetbond, 3M, Maplewood, MN) and 2‐0 nylon suture (Medtronic, Watford, UK). Using 1″ white tape, a butterfly was placed directly behind the white suture wing encompassing the catheter to prevent the exterior catheter from being inadvertently introduced further, and to monitor for catheter withdrawal. An antimicrobial incisable drape (Ioban 2, 3M Brookings, SD) was applied to the area, leaving only the clamp adapter with injection port accessible. Elastic bandage material (Elastikon, Essity, Pinetown, South Africa) was applied over the entire drape for further protection from environmental and mechanical disruption. After the first day of sampling, ITC were aseptically flushed with 1 mL of a sterile saline solution 12 h after daily samples were obtained. Injection caps were replaced every 24 h before sampling or sooner if indicated. The elastic bandage was replaced as needed. Horses 3–6 were administered 1.1 mg/kg of flunixin meglumine (Banamine, Merck Animal Health, NJ) intravenously following successful placement of the indwelling ITC. Diclazuril Administration Horses were administered 1 mg/kg of diclazuril pellets (Protazil, Merck Animal Health, Rahwway, NJ, USA) which amounted to 50 mL for five horses and 60 mL of pellets for 1 horse, using the product‐specific measuring cup. Pellets were given with 1 cup of sweet feed (Omolene 300, Purina Animal Nutrition, Arden Hills, MN). Horses were fed individually with direct supervision to ensure the entire dose was consumed. All doses were consumed within 5 min of offering. Plasma Collection At time of initial catheter placement, whole blood was collected into additive‐free and lithium heparinized tubes (BD Vacutainer, Franklin Lakes, NJ) for negative controls and EPM testing. Whole blood was collected at 0‐, 1‐, 4‐, 8‐, 12–16‐, 24‐, 48‐, 72‐, 96‐, 120‐, 144‐, and 168‐h, following a single oral dose of diclazuril. Samples were drawn from indwelling IVCs, or by direct venipuncture if a catheter failed, into lithium heparin tubes (BD Vacutainer, Franklin Lakes, NJ). Twelve milliliters of blood was discarded before collecting 10 mL for the sample when a catheter was in place. Catheters were flushed with 12 mL heparinized saline solution following all sample collections. Blood was centrifuged for 10 min at 2000 x g and plasma was collected and stored in cryogenic vials (Corning, Tewksbury, MA) at −80°C within 1 h of collection. CSF Collection At the time of ITC placement, 10 mL of CSF was obtained from every horse and stored at −80°C for baseline assay controls and for individual EPM testing. Additional CSF was collected at 0‐, 1‐, 4‐, 8‐, 12–16‐, 24‐, 48‐, 72‐, 96‐, 120‐, 144‐, and 168‐h following a single oral dose of diclazuril. To account for catheter dead space (maximum 0.37 mL), a 0.5 mL waste sample was discarded prior to collecting a 1 mL sample for analysis. The 1 mL sample was transferred directly to an additive‐free vial (BD Vacutainer, Franklin Lakes, NJ), centrifuged for 10 min at 2000×g, and supernatant transferred to a cryogenic vial (Corning, Tewksbury, MA) and stored at −80°C within 1 h of collection. Plasma and CSF Analysis Frozen plasma and CSF samples were transferred to the Clinical Pharmacology Laboratory at North Carolina State University. Plasma and CSF samples were analyzed for diclazuril using high‐pressure liquid chromatography (HPLC) paired with mass spectrometry detection (LC–MS) using a validated method developed in the Clinical Pharmacology Laboratory at North Carolina College of Veterinary Medicine. This laboratory uses the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) (available at: https://database.ich.org/sites/default/files/ICH_Q22_Document_Step‐R2_Guideline_2022_0324.pdf) and the guidelines published in Chapter 1225 of the United States Pharmacopeia (www.USP.org) as a guide to method acceptance and validation. Incurred plasma samples, calibration samples, and QC samples were prepared by pipetting 500 μL of plasma into a clean tube and adding 1000 μL (1 mL) of acetonitrile. After vortexing, the samples were centrifuged for 5 min at 20,000×g, and 1000 μL of supernatant was harvested. The supernatant was dried in an evaporator under an air flow of 20 psi at 40°C for 20 min. The dry residue was reconstituted with 250 μL of a mixture of 50% water/50% acetonitrile and transferred to injection vials (Whatman UN503NPEAQU syringeless filter device. Pore size 0.2 μm). For the CSF, 250 μL of CSF was mixed with an equal volume of acetonitrile and vortexed. This mixture was added to the injection vials described above. Following extraction and reconstitution, the samples were injected into the LC–MS system that consisted of a quaternary solvent delivery system at a flow rate of 1.0 mL/min (Agilent 1260 Solvent Delivery System, Agilent Technologies, Wilmington, DE), an autosampler (Agilent 1260 Autosampler, Agilent Technologies, Wilmington, DE), and a mass spectrometer (Agilent 61060A LC/MSD iQ, Agilent Technologies, Wilmington, DE). Diclazuril has a molecular mass of 405.98 Da and the mass spectrometer was run in Auto Acquire single ion monitoring mode (SIM), with negative ionization and a mass/charge (m/z) of 407.2. Chromatograms were integrated with a computer program (Agilent OpenLAB CDS software, Agilent Technologies, Wilmington, DE). The analytical column was a reverse‐phase column (Zorbax Eclipse XDB‐C8 4.6 × 15; 5 μm) kept at a constant temperature of 40°C. The mobile phase consisted of 60% acetonitrile and 40% 0.1% formic acid in water. Fresh mobile phase was prepared, filtered (0.45 μm), and degassed for each daily run. A pure analytical reference standard of diclazuril was obtained from the United States Pharmacopeia (www.USP.org; Catalog No: 1188560; CAS RN 101831‐37‐2). The reference standard was dissolved in dimethylformamide (DMF), with additional dilutions in 40% acetonitrile/60% water. These solutions were used as a spiking solution for quality control samples (QC) and calibration curve standards. Calibration curve samples and QC samples were prepared by fortifying blank (control) equine plasma and CSF with standard solutions of diclazuril. Calibration curve standards and QC samples were prepared fresh daily for each run. The plasma incurred samples were quantified using a calibration curve that consisted of fortified blank equine plasma with seven calibration standards ranging from 1.95–500 ng/mL and included a blank (0 ng/mL). The CSF samples were in a lower concentration range. Therefore, a different calibration curve range was used for these samples with a range of 0.39–12.5 ng/mL. Pharmacokinetic Analysis Plasma and CSF concentrations of diclazuril after the oral dose were plotted on a semi‐logarithmic graph. Visual examination of the plot helped define the best analysis for these data. Analysis of curves and PK modeling were performed using commercial PK software (Phoenix software WinNonlin, Phoenix, Version 8.5, Certara, St. Louis, MO). One‐, two‐, and three‐compartment models were tested, with various weighting factors. Goodness‐of‐fit criteria and observation of observed vs. predicted plots were used to select the best model that fit these data. For this oral dose, absorption rate, elimination rate, and volume of distribution were calculated using the following formula: where C is the plasma concentration, T is time (h), K01 is the non‐IV absorption rate assuming first‐order absorption, K10 is the elimination rate constant, V is the apparent volume of distribution, F is the fraction of drug absorbed, and D is the non‐IV dose. In this model, it is assumed that K 01 >>>K 10, or that there is no “flip‐flop” effect caused by slow absorption from the GI tract. Secondary parameters from the model include the peak concentration (C MAX), time to peak concentration (T MAX), area under the plasma‐concentration versus time profile (AUC), and the respective absorption and terminal half‐lives (T½). Absolute bioavailability of the oral dose (%F) cannot be calculated without an accompanying IV dose. Because the fraction absorbed cannot be calculated, the CL/F and V/F have no meaning and were not reported. The ratio of the concentrations in the CSF/plasma for the C MAX and AUC values was also calculated as a measure of the relative extent of penetration of diclazuril to the CSF. Results Plasma and CSF Analysis The plasma and CSF analysis were successfully performed using the LC–MS method described. The lower limit of quantitation (LLOQ) for the assay was 7.8 ng/mL for the plasma and 0.39 ng/mL for the CSF, which was determined by the lowest point on the linear calibration curve that met our criteria for acceptance. All incurred plasma samples measured (except for the time zero sample) were above these values. Some CSF samples had undetectable concentrations and were recorded as “0” while those results below the LLOQ were excluded from analysis. The assay met our validation requirements with a calibration curve R 2 at least 0.99 on each day of the analysis with quality control (QC) samples back‐calculated to within 15% of the nominal concentration. During our validation procedure, and on each day of the analysis, the accuracy of the assay was within our acceptance criteria of ±15% of the nominal concentration and the precision of replicate samples tested at the low, medium, and high range was within 15% coefficient of variation. Plasma and CSF concentrations are shown in Figure 1 with the mean points and sample standard deviation for each matrix. The pharmacokinetic results for each matrix are presented in Tables 1, 2, 3. The plotted observed vs. predicted points from each horse in the pharmacokinetic analysis are shown in Figures 2 and 3. The plasma concentrations demonstrated a long half‐life that persisted to the last sample point. The concentrations were consistent among horses with a coefficient of variation (CV%) for most parameters approximately in the 20%–35% range (Tables 1 and 3). The CSF concentrations also demonstrated a long half‐life (Tables 2 and 3). The appearance in the CSF mirrored the rise in plasma concentrations (Figure 1) with the peak (T MAX) occurring at approximately the same time (Tables 2 and 3). The rate of penetration into the CSF can be inferred from the CSF K01 half‐life value of approximately 13 h. However, the CSF concentrations were much lower than the plasma concentrations, with a CSF/plasma concentration ratio of approximately 2% for the AUC and C MAX concentrations. These concentrations were also much more variable with a higher CV% for the pharmacokinetic parameters (Tables 2 and 3). One source of this variability was from Horse #2 (Table 2; Figure 3) that had very low CSF concentrations, despite plasma concentrations in a similar range as the other horses. Concentrations of diclazuril in the plasma and CSF from six horses administered a single oral dose of 1 mg/kg. The solid red points represent the mean plasma concentrations (±SD) and the solid square blue points represent the mean CSF concentrations (±SD). TABLE 1Diclazuril pharmacokinetic values from analysis of plasma concentrations in 6 horses administered a single dose of 1 mg/kg. A one‐compartment model with first order elimination was fitted to each horse's data.ParameterUnitsHorse 1Horse 2Horse 3Horse 4Horse 5Horse 6MeanSDAUCh*ng/mL53,921.3354,968.2679,569.9442,885.5651,024.91107,120.9864,915.1624,058.85 C MAX ng/mL446.82400.32488.94278.05313.86448.36396.0683.24K011/h0.0450.0500.0350.0550.0220.0500.0430.012K01 T½h15.4313.8619.8612.6331.2114.0017.837.02K101/h0.01410.01120.01020.00930.01320.00550.01060.0031K10 T½h49.2761.7867.8474.4052.62125.8071.9527.98 T MAX h37.6338.5249.7738.9157.8149.8945.428.28Abbreviations: AUC, area‐under‐the‐curve; C MAX, peak concentration; K01, absorption rate constant, and associated half‐life (T½); K10, elimination rate constant, and associated half‐life (T½); T MAX, time to peak concentration. Diclazuril pharmacokinetic values from analysis of plasma concentrations in 6 horses administered a single dose of 1 mg/kg. A one‐compartment model with first order elimination was fitted to each horse's data. Abbreviations: AUC, area‐under‐the‐curve; C MAX, peak concentration; K01, absorption rate constant, and associated half‐life (T½); K10, elimination rate constant, and associated half‐life (T½); T MAX, time to peak concentration. TABLE 2Diclazuril pharmacokinetic values from analysis of CSF concentrations in 6 horses administered a single dose of 1 mg/kg. A one‐compartment model with first order elimination was fitted to each horse's data.ParameterUnitsHorse 1Horse 2Horse 3Horse 4Horse 5Horse 6MeanSDAUChr*ng/mL1255.20286.801268.253924.311497.182085.961719.621226.11 C MAX ng/mL8.071.677.8817.019.528.938.844.90K011/h0.0990.0930.0170.0560.0670.0400.0620.031K01 T½h6.987.4141.3912.2910.3117.2415.9413.02K101/h0.00800.00720.01700.00560.00860.00600.00870.0042K10 T½h86.3996.3340.73124.0280.67116.1290.7129.68 T MAX h27.5729.7259.2445.5035.0855.7142.1413.45CSF/Plasma C MAX Ratio0.0180.0040.0160.0610.0300.0200.0250.020CSF/Plasma AUCRatio0.0230.0050.0160.0920.0290.0190.0310.031 Note: The CSF/Plasma ratio are the ratios of CSF C MAX or AUC, respectively, taken from a ratio of each horse.Abbreviations: AUC, area‐under‐the‐curve; C MAX, peak concentration; K01, absorption rate constant, and associated half‐life (T½); K10, elimination rate constant, and associated half‐life (T½); T MAX, time to peak concentration. Diclazuril pharmacokinetic values from analysis of CSF concentrations in 6 horses administered a single dose of 1 mg/kg. A one‐compartment model with first order elimination was fitted to each horse's data. Note: The CSF/Plasma ratio are the ratios of CSF C MAX or AUC, respectively, taken from a ratio of each horse. Abbreviations: AUC, area‐under‐the‐curve; C MAX, peak concentration; K01, absorption rate constant, and associated half‐life (T½); K10, elimination rate constant, and associated half‐life (T½); T MAX, time to peak concentration. TABLE 3Diclazuril pharmacokinetic value statistics from analysis of Plasma and CSF concentrations in 6 horses administered a single dose of 1 mg/kg.ParameterUnitsMeanSDGeometric meanGeometric CV% Plasma statistics AUCh*ng/mL64915.1624058.8561720.8034.72 C MAX ng/mL396.0683.24388.1922.70K011/h0.0430.0120.04134.78K01 T½h17.837.0216.9134.78K101/h0.01060.00310.010134.60K10 T½h71.9527.9868.3234.60 T MAX h45.428.2844.8118.08 CSF statistics AUCh*ng/mL1719.621226.111332.42105.62 C MAX ng/mL8.844.907.3191.16K011/h0.0620.0310.05473.91K01 T½h15.9413.0212.9373.91K101/h0.00870.00420.008141.64K10 T½h90.7129.6885.6241.64 T MAX h42.1413.4540.3533.24CSF/Plasma C MAX Ratio0.0250.0200.01978.60CSF/Plasma AUCRatio0.0310.0310.022100.07Abbreviations: AUC, area‐under‐the‐curve; C MAX, peak concentration; K01, absorption rate constant, and associated half‐life (T½); K10, elimination rate constant, and associated half‐life (T½); T MAX, time to peak concentration. For the CSF analysis, the CSF/Plasma ratio are the ratios of CSF C MAX or AUC, respectively taken from a ratio of each horse. Diclazuril pharmacokinetic value statistics from analysis of Plasma and CSF concentrations in 6 horses administered a single dose of 1 mg/kg. Abbreviations: AUC, area‐under‐the‐curve; C MAX, peak concentration; K01, absorption rate constant, and associated half‐life (T½); K10, elimination rate constant, and associated half‐life (T½); T MAX, time to peak concentration. For the CSF analysis, the CSF/Plasma ratio are the ratios of CSF C MAX or AUC, respectively taken from a ratio of each horse. Individual model fit d plots for each horse. Plasma concentrations. Individual model fit d plots for each horse. CSF concentrations. Discussion The objective of this study was to evaluate the plasma and CSF concentrations of diclazuril after a single oral dose, and we hypothesized that diclazuril concentrations would reach concentrations > 1 ng/mL in the CSF within 24 h. As previously described, cell cultures of S. neurona were > 95% inhibited with diclazuril concentrations in the CSF of 1 ng/mL (Lindsay and Dubey 2000). The results of the present study revealed that all horses reached a concentration > 1 ng/mL in CSF within 12 h of a single oral 1 mg/kg dose of diclazuril. In line with earlier studies, our results also support that there is no need for a loading dose or administration with absorption‐enhancing products (Schering‐Plough Animal Health Corp 2007; Hunyadi et al. 2018). A major limitation of our study is that we used CSF concentrations as a surrogate for predicting the concentrations in the brain and meninges of horses infected with S. neurona. It is well understood that these compartments are not equal, and other studies have been criticized for making this assumption (Pardridge 2011). The barriers for a drug to penetrate from the blood or CSF to the brain parenchyma are well‐known (Pardridge 2012). There is a high flow rate and turnover of CSF that follows the path of diffusion from the choroid plexus to reabsorption into the blood by the arachnoid villi. Diffusion of drug from the CSF to the brain is minimal and most of the drug that enters the CNS parenchyma comes from circulating blood. Thus, most of the drug in the CSF enters the CNS parenchyma by first diffusing back into the blood followed by diffusion from blood across the blood–brain barrier (Pardridge 2011). Considering S. neurona is an obligate intracellular parasite, the most relevant drug concentrations are those within CNS intracellular compartments (Lindsay et al. 2006). More invasive techniques—such as intracerebral microdialysis, PET imaging, or MR spectroscopy—would be more accurate to measure intracellular compartment concentrations of diclazuril, but have not been validated in equine pharmacokinetic studies and are not readily available (De Lange and Danhof 2002). We used the CSF concentrations as a surrogate for the CNS concentration because it was the only tissue fluid that could be collected without invasive procedures from healthy horses. Sampling of the brain and meningeal fluid from horses would require animal sacrifice or insertion of invasive microdialysis probes into the brain (Bickel 2005). Without additional experiments, we cannot be certain that our CSF concentration results reflect the concentrations in brain and meningeal fluid. Another limitation of our study was sampling after just a single dose instead of waiting until steady‐state conditions from multiple doses. Previous studies measured plasma or CSF concentrations at steady state and showed that repeated doses accumulate until steady‐state was achieved (Hunyadi et al. 2018, 2015; Pusterla et al. 2023). Those studies measured higher concentrations, which allowed for an HPLC‐UV method with high assay detection limits. Because we anticipated lower concentrations in the CSF based on pilot studies, we developed a new LC–MS assay designed to detect low concentrations of diclazuril in CSF within the first 24 h after a single oral dose. This assay successfully measured low CSF concentrations, with a lower limit of quantification (LOQ) of 0.39 ng/mL. This novel method may be useful for future studies evaluating early CNS drug penetration before steady‐state. Like other studies, the concentration in the CSF was low compared to the plasma concentrations: approximately 2% for the peak (C MAX) and AUC concentrations (Hunyadi et al. 2015). There are many factors affecting drug transport from the blood to the CSF. Ordinarily, the blood‐CSF barrier is very leaky compared to the blood–brain barrier (Pardridge 2011). The properties that favor drug transport across the blood‐CSF barrier are a molecular weight < 400 Da, high lipophilicity with a partitioning coefficient (log P) > 2, and < 7 hydrogen bonds (Shen et al. 2004). Diclazuril meets, or is close to, these criteria with—according to PubChem (PubChem; https://pubchem.ncbi.nlm.nih.gov/)—a molecular weight of 407.6 Da, a Log P of 4.1, and 5 hydrogen bonds. These properties should predict high penetration. Therefore, the best explanation for the low CSF/plasma ratio in our study is high plasma protein binding since the CSF/unbound plasma concentration ratio is near unity or above unity for drugs with high lipid solubility (Shen et al. 2004). The present study did not measure the protein binding of diclazuril in plasma or CSF and is considered a limitation. Our LC–MS assay for plasma and CSF removed the proteins during processing, and we measured total (free and unbound) concentrations. However, because protein does not ordinarily cross the blood‐CSF barrier, we anticipate that the protein‐bound fraction in CSF is negligible. Without further investigation and protein binding studies, we cannot determine the cause for the relatively lower CSF concentration in our horses when compared to plasma concentrations. Despite the low CSF/plasma concentrations we observed, all horses had diclazuril concentrations in the CSF > 1 ng/mL within 12 h and remained above that threshold for all measured timepoints. One horse (Horse 2) had lower CSF concentrations compared to the other animals, indicating unaccounted‐for variability among animals. The authors cannot speculate on the reason(s) for Horse 2's overall lower CSF concentrations compared to others in the study. This data may encourage practitioners to consider individual variability in horses who are diagnosed with EPM but are refractory to treatment. Further research is necessary to provide solutions in cases of treatment failure. Typically, CSF contains approximately < 1/100th the protein concentration compared to plasma, with albumin accounting for the majority of the protein (Fish and Bertone 2020; De Lahunta et al. 2021). In diseases where CSF protein concentration may increase, free‐drug availability may be impacted, affecting drug activity for those individuals. This study should serve as a foundation for future research to determine whether unbound plasma concentrations of diclazuril correlate with CSF concentrations, thus identifying whether plasma measurements could be a reliable, less invasive surrogate for diclazuril monitoring, particularly for horses that fail to respond to treatment. Without the use of indwelling intrathecal catheters, this frequency of CSF sampling would be impossible without repeated heavy sedation or general anesthesia protocols, which pose a greater risk to the animal and investigator. No adverse effects were observed from oral drug administration or IVCs during the study period. One horse was moderately sensitive to palpation over the lumbosacral area following ITC catheter placement, which resolved with NSAID administration. One horse had mild sensitivity to CSF aspiration and catheter manipulation when adjustments (pulling the catheter out by small increments) were necessary to regain patency. The earliest ITC failure occurred at 72 h, while the others remained patent for 144–192 h (6–8 days). The loss of sample concentrations from one horse after 72 h did not affect the pharmacokinetic analysis. Three catheters (50%) were patent at the intended study end (192 h), which demonstrates that prolonged intrathecal catheterization is feasible; however, complications with CSF aspiration may prompt researchers to use larger study populations to account for data lost to catheter failure. Conclusion In conclusion, all horses in our study had diclazuril CSF concentrations greater than the MIC for S. neurona (> 1 ng/mL) 12 h after a single oral dose. CSF concentrations were approximately 2% of plasma concentrations for peak and AUC concentrations. Despite the inherent limitations of equating CSF drug concentrations to brain extracellular fluid or intracellular concentrations, these results provide a closer approximation than plasma alone. Without more invasive collection methods, CSF concentrations may provide an approximation of diclazuril transport across membranes to other tissues, including the brain and meninges. Indwelling lumbosacral subarachnoid catheters were effective and well‐tolerated; this sampling technique may be used for future investigations regarding drug transport across membranes in horses. These data show that clinicians can feel confident that administration of oral diclazuril will be rapidly absorbed to reach peak plasma concentrations within 48 h and concentrations in other tissue fluids, including the CSF, follow the same profile. Author Contributions E.J. Treece – study design, sample collection, data curation, manuscript preparation. K.L. Hepworth‐Warren – study design, sample collection, data curation, manuscript preparation. M.G. Papich – study design, data analysis, manuscript preparation. P.D. van Harreveld – study design, manuscript preparation. A.T. Blikslager – study design, sample collection, manuscript preparation. F.E. Church – sample collection, manuscript preparation. K.B. Harbor – sample collection, manuscript preparation. S.J. Erwin‐Craig – sample collection, manuscript preparation. All authors contributed to manuscript preparation and reviewed and approved the final submission. Funding This study was funded by a research grant from Merck Animal Health (Grant #PAM‐P25‐000284). Disclosure Animal Welfare and Ethics Statement: All procedures were approved by the North Carolina State University Institutional Animal Care and Use Committee, and the authors confirm adherence to United States standards for the protection of animals used for scientific purposes. The authors confirm that the ethical policies of the Journal of Veterinary Pharmacology and Therapeutics, as defined on the authors' guideline page, have been followed. Conflicts of Interest The authors E.J. Treece, K.L. Hepworth‐Warren, A.T. Blikslager, F.E. Church, S.J. Erwin‐Craig, and K.B. Harbor have no conflicts of interest to declare. P.D. van Harreveld is an employee of Merck Animal Health. M.G. Papich has been a paid consultant for work unrelated to this study, and his laboratory received research support from Merck. He received no compensation for this project. M.G. Papich is an editor for the present journal. Acknowledgements This study was funded by a research grant from Merck Animal Health. The authors would like to thank Tiffany Pridgen for her assistance during sample collection. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.